ReviewTherapeutic advances in medical oncology2025
The emerging role of IL-17A across different types of radiation-induced normal tissue injuries.
Review in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced normal tissue injuries (RITIs) are the main complications that can significantly limit the use of radiotherapy and affect clinical outcomes in patients with cancer. This article aims to review current literature on the role of proinflammatory cytokine interleukin (IL)-17A in different types of RITIs. While irradiation significantly increases IL-17A expression in normal tissues, activated IL-17A plays a dual role of both promoting and protecting against RITIs, depending on the tissue type. These novel findings have led to a strong interest in evaluating the therapeutic potential of targeting IL-17A/IL-17 receptor signals in RITIs in different normal tissues. Preliminary results from preclinical animal models have shown that blocking IL-17A/IL-17 receptor signaling after irradiation significantly reduces the pathogenesis of RITIs in the skin and lung but enhances it in the intestine and oral mucosa. However, the mechanisms underlying the tissue-dependent dual roles of IL-17A in RITIs remain elusive. Therefore, future studies focusing on the precise role and mechanism of IL-17A action in different RITIs are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.